Aromatase inhibitors and bone.
The decrease in estrogen levels with the use of aromatase inhibitors results in an increase in the rate of bone remodelling. This result in an acceleration of bone loss, and probably to an increase in the risk of fractures. The risk of fracture is particularly high in the older woman and in the woman with a low bone mineral density. We have a number of proven treatments for the treatment of postmenopausal osteoporosis and it is likely that some of these, particularly bisphosphonates, could be effective at preventing bone loss with aromatase inhibitors.
Eastell
Richard
R
The Academic Unit of Bone Metabolism, Musculoskeletal Section, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK. r.eastell@sheffield.ac.uk
D000368:Aged; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D012307:Risk Factors
D047072:Aromatase Inhibitors